drugset
Drugs / AMA1-C1
last change Mar 2013 re-read 9 days ago

AMA1-C1

also known as AMA1-C1Alhydrogel

Vaccine

Developed for
malaria · Plasmodium falciparum malaria
Investigated by
National Institute of Allergy and Infectious Diseases (NIAID) · University of Oxford

Trials 11

today NCT01351948 · Ph 1 NCT00984763 · Ph 1/2 NCT00740090 · Ph 1 NCT00487916 · Ph 1 NCT00427167 · Ph 1 NCT00414336 · Ph 1 NCT00341250 · Ph 1/2 NCT00344539 · Ph 1 NCT00114010 · Ph 1 NCT00340574 · Ph 1 NCT00343005 · Ph 1
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT01351948 Jun 2011 → Mar 2013 malaria University of Oxford Completed No outcome recorded
Phase 1 NCT00740090 Aug 2008 → Jun 2009 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00487916 Jun 2007 → Feb 2009 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00427167 Jan 2007 → Nov 2008 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00414336 Dec 2006 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00344539 May 2005 → Jan 2007 Plasmodium falciparum malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00114010 Apr 2005 → Dec 2006 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00340574 Mar 2005 → Jul 2008 — National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT00343005 Apr 2004 → Jan 2008 Plasmodium falciparum malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1/22 trials · 1 missed
Phase 1/2 NCT00984763 Jan → Sep 2010 malaria University of Oxford Completed Missed primary
Phase 1/2 NCT00341250 Jan → Dec 2006 malaria National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as AMA 1-C1 “This study will examine the safety and immune response of healthy adult volunteers to AMA1-C1, an experimental malaria vaccine developed by the NIAID.” NCT00114010 ↗
12

“AMA1 C1 is made from a synthetic protein similar to a P. falciparum protein.” NCT00740090 ↗

“80 microg of AMA 1-C1 formulated in ISA 720.” NCT00487916 ↗

NCT00984763 ↗

NCT00740090 ↗

NCT00427167 ↗

NCT01351948 ↗

NCT00343005 ↗

NCT00344539 ↗

NCT00487916 ↗

NCT00414336 ↗

Show 2 more sources
Known as AMA1-C1Alhydrogel “The vaccine, called AMA1-C1Alhydrogel (or AMA1-C1), contains a small part of the malaria-causing germ.” NCT00414336 ↗
1

“AMA1-C1/Alhydrogel® vaccine” NCT00344539 ↗
Action Inhibit “Therefore, this vaccine was designed to protect an individual from illness due to the asexual stage of P. falciparum infection by inhibiting parasite invasion of erythrocytes.” NCT00343005 ↗
Modality Vaccine “AMA1-C1, an experimental malaria vaccine developed by the NIAID” NCT00114010 ↗
Route Intramuscular “The shots are given in an upper arm muscle” NCT00114010 ↗